Turkey’s Antitrust Watchdog Launches Probe of Teva Over Rival Generic Blocking
Turkey’s Competition Authority has opened an antitrust investigation into Teva over allegations that it blocked rival generic medicines. The probe follows a preliminary inquiry into whether Teva engaged in conduct meant to restrict competition, including practices tied to divisional patent applications. The case also comes amid Teva’s prior EU antitrust fine in 2024 related to Copaxone.